Aripiprazole is used alone or together with other variables to treat mental conditions such as atypical I disorder manic-depressive illness, major depressive episode, and schizophrenia. It is also ...

Aripiprazole (Abilify, Otsuka Pharmaceuticals Europe) is an antipsychotic with partial dopamine D2 and D3 agonistic properties. It has a UK marketing authorisation 'for the treatment up to 12 weeks of ...

It may also be used in combination with other medication to treat depression. Aripiprazole is known as an antipsychotic drug atypical type. This medication can decrease hallucinations and improve your ...

June 20, 2007 — A large, international clinical trial in teens with schizophrenia demonstrated that the atypical antipsychotic aripiprazole (Abilify, Otsuka Pharmaceutical Co and Bristol-Myers Squibb) ...

Abstract and Introduction Clinical Profile of Aripiprazole as Reflected by Clinical Trial Data Use of Aripiprazole in the Treatment of Schizophrenia: Consensus Report Conclusion References Weight and ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Aripiprazole (Arpicin (30 mg)) is an atypical antipsychotic and antidepressant, prescribed for schizophrenia and depression. It regulates abnormal conditions like disturbed or unusual thinking, loss ...

Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation. Relapse prevention is an important consideration ...